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ABSTRACT
Purpose To develop a new intradermal antigen delivery sys-
tem by coating microneedle arrays with lipid bilayer-coated,
antigen-loaded mesoporous silica nanoparticles (LB-MSN-
OVA).
Methods Synthesis of MSNs with 10-nm pores was per-
formed and the nanoparticles were loaded with the model
antigen ovalbumin (OVA), and coated with a lipid bilayer
(LB-MSN-OVA). The uptake of LB-MSN-OVA by bone
marrow-derived dendritic cells (BDMCs) was studied by flow
cytometry. The designed LB-MSN-OVA were coated onto
pH-sensitive pyridine-modified microneedle arrays and the
delivery of LB-MSN-OVA into ex vivo human skin was
studied.
Results The synthesized MSNs demonstrated efficient load-
ing of OVA with a maximum loading capacity of about 34%
and the lipid bilayer enhanced the colloidal stability of the
MSNs. Uptake of OVA loaded in LB-MSN-OVA by
BMDCs was higher than that of free OVA, suggesting effec-
tive targeting of LB-MSN-OVA to antigen-presenting cells.
Microneedles were readily coated with LB-MSN-OVA at
pH 5.8, yielding 1.5 μg of encapsulatedOVA permicroneedle
array. Finally, as a result of the pyridine modification, LB-
MSN-OVA were effectively released from the microneedles
upon piercing the skin.
Conclusion Microneedle arrays coated with LB-MSN-
OVA were successfully developed and shown to be suit-
able for intradermal delivery of the encapsulated protein
antigen.
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ABBREVIATIONS
AEP-
MSNs
AEPTMS-modified MSNs
AEPTMS 3-[2-(2-aminoethylamino)ethylamino]
propyltrimethoxysilane
BDMCs Bone marrow-derived dendritic cells
DOPC 1,2-dioleoyl-sn-glycero-3-phosphocholine
DOPE-LR 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-(lissamine rhodamine
B sulfonyl) (ammonium salt)
DOPS 1,2-dioleoyl-sn-glycero-3-[phospho-L-
serine](sodium salt)
EE Encapsulation efficiency
LB-MSN-
OVA
Lipid bilayer-coated and antigen-loaded AEP-
MSNs
LC Loading capacity
MSNs Mesoporous silica nanoparticles
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INTRODUCTION
Vaccination is regarded as one of the most promising strate-
gies for reducing mortality and improving human health (1,2).
Most of the current vaccines are delivered by intramuscular or
subcutaneous injection, which have inherent limitations, such
as the risk of infections induced by reusing needles and syrin-
ges and the needle fear of children and patients. Therefore,
new needle-free, easy to use and effective vaccinationmethods
are urgently needed. One of these potential methods is
microneedle-mediated intradermal vaccination (3).
Intradermal vaccination is attractive because the skin is
easily accessible and harbors a large number of immune cells,
such as dendritic cells (DCs) (1,4). Microneedles are micron-
sized structures with a length of less than 1 mm which can be
used to overcome the skin barrier located in the top layer of
the skin. As these needles do not penetrate to the depths where
nerve endings reside, coating of antigens on microneedles en-
ables minimally-invasive and pain-free delivery of vaccines
into skin (5–7). A major challenge however, is the limited dose
that can be delivered with coated microneedles. In an effort to
improve coating efficiency, our lab designed pH-sensitive pyr-
idine-modified microneedles with a surface pKa below physi-
ological pH, which allows the adsorption of negatively-
charged proteins at slightly acidic conditions (pH 5.8) and
their release at neutral pH (pH 7.4). In our previous study,
intradermal immunization using pH-sensitive microneedles
coated with 5.7 μg OVA was compared to conventional sub-
cutaneous or intradermal immunization (8,9). Microneedle-
mediated immunization led to comparable T-cell responses
but 10-fold lower IgG responses when compared to conven-
tional subcutaneous or intradermal immunization. Possible
strategies to further improve the immunogenicity of vaccines
by the intradermal route could be adding an adjuvant or using
nanoparticles to deliver the antigens (2,6,10–13).
The adjuvanticity of nanoparticles is attributed to their
capability of protecting antigens from degradation, forming
a depot at the site of injection, and facilitating antigen uptake
by DCs (14). A variety of nanosized vaccine delivery sys-
tems have been developed, such as polymeric nanoparti-
cles (15), emulsions (16), and lipid-based nanoparticles
(15,17). Recently mesoporous silica nanoparticles (MSNs)
have gained significant attention as drug delivery vehicles
because of their controlled size and mesostructure, excel-
lent in vivo biocompatibility, and their large surface area
and pore volume, enabling the efficient loading of active
small molecules or proteins (2,18–21).
Herein, we report a new intradermal delivery system,
which synergistically integrates the advantages of nanoparti-
cles and microneedles by coating pH-sensitive microneedles
with antigen-loaded, lipid bilayer-covered MSNs. As a model
antigen, OVA was used. This protein is negatively charged (pI
of 4.9) (22) at pH 7.4. For the delivery of OVA, a novel type of
ultrafine MSNs with large pores (~10 nm in diameter) was
synthesized with a positive surface charge (AEP-MSNs),
resulting in efficient loading of OVA in the AEP-MSN pores.
To enhance the colloidal stability of OVA-loaded AEP-MSNs
and generate a negative surface charge, a negatively charged
lipid bilayer (LB) was assembled at the AEP-MSN surface and
the lipid-coated and OVA-loaded AEP-MSNs are referred to
as LB-MSN-OVA (23–25). This method synergistically com-
bines features of liposomes and MSNs and has been reported
to address the multiple challenges including stability, targeting
and multicomponent delivery (24,25). The designed LB-
MSN-OVA were coated onto pH-sensitive pyridine-modified
silicon microneedles by electrostatic interactions between the
pyridine groups and the LB-MSN-OVA at low ionic strength.
Piercing the LB-MSN-OVA coated microneedles into ex vivo
human skin resulted in the successful release of the nanopar-
ticles due to a shift in pH from 5.8 to 7.4 (Scheme 1).
MATERIALS AND METHODS
Materials
Tetraethyl orthosilicate (TEOS, 98%), sulfuric acid (96%–98%),
hydrochloric acid (36%–38%), (3-aminopropyl)triethoxysilane
(APTES, 99%), 4-pyridinecarboxaldehyde (97%), sodium
cyanoborohydride (95%), 3-[2-(2-aminoethylamino)ethylamino]
propyltrimethoxysilane (AEPTMS, technical grade),
Ovalbumin (OVA, ≥98%), 1,3,5-trimethylbenzene (TMB,
97%), Pluronic P123 (EO20PO70EO20, Mn ∼ 5800 g/mol),
and cholesterol (≥99%) were purchased from Sigma-
Aldrich (Zwijndrecht, the Netherlands). Fluorocarbon sur-
factant FC-4 was purchased from Yick-Vic Chemicals &
Pharmaceuticals (HK) Ltd. 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-
3-[phospho-L-serine](sodium salt) (DOPS), and 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine
rhodamine B sulfonyl) (ammonium salt) (DOPE-LR) were
purchased from Avanti Polar Lipids Inc. (Alabaster, AL).
Hydrogen peroxide (30%) and ethylenediaminetetraacetic
acid (EDTA) were purchased from Fluka (Steinheim,
Germany). Toluene (≥99.7%) was purchased from
Biosolve (Valkenswaard, the Netherlands) . Alexa
Fluor®488 ovalbumin conjugates (OVA-AF488), anti-
CD40-FITC, anti-CD80-PE and anti-CD86-APC were
purchased from Thermo Fisher Scientific (Waltham,
MA). Sterile phosphate buffered saline (PBS, 163.9 mM
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Na+, 140.3 mM Cl−, 8.7 mM HPO4
2−, 1.8 mM H2PO4
−,
pH 7.4) was obtained from Braun (Oss, the Netherlands).
All the other chemicals used are of analytical grade and
used without further purif icat ion. Mil l i -Q water
(18.2 MΩ/cm, Millipore Co., USA) was used for the prep-
aration of solutions. 1 mM phosphate buffer (PB) with a
pH of 7.4 was prepared in the lab. Silicon microneedle
arrays with 576 microneedles per array on a back plate
of 5 × 5 mm2 and a length of 200 μm per microneedle
were kindly provided by Robert Bosch GmbH (Stuttgart,
Germany).
Synthesis of MSNs and Amino-Functionalized MSNs
(AEP-MSNs)
Mesoporous silica nanoparticles were synthesized accord-
ing to a published procedure with modifications (26).
Briefly, surfactant Pluronic P123 (0.5 g) and FC-4 (1.4 g)
were dissolved in HCl (80 mL, 0.02 M), followed by the
introduction of TMB (0.48 mL). After stirring for 6 h,
TEOS (2.14 mL) was added dropwise. The resulting mix-
ture was stirred at 30°C for 24 h and transferred to an
autoclave at 120°C for 2 days. Finally, the solid product
was isolated by centrifugation, and washed with ethanol
and Milli-Q water. The organic template was completely
removed by calcination at 550°C for 5 h.
To prepare cationic MSNs, AEPTMS in absolute ethanol
(4 mL, 20 wt%) was incubated with MSNs (100 mg) overnight
at room temperature. The desired AEP-MSNs were collected
by centrifugation and washed with ethanol to remove
unreacted AEPTMS.
Characterization of MSNs and AEP-MSNs
Morphology of MSNs and AEP-MSNs was visualized by
transmission electron microscopy (TEM) using a JEOL 1010
instrument (JEOL Ltd., Peabody, MA) with an accelerating
voltage of 70 kV. To prepare the samples, several droplets of
nanoparticle suspension (1 mg/ml) were put on a copper grid,
dried overnight and coated with carbon.
Nitrogen adsorption-desorption isotherms of samples were
obtained with a TriStar II 3020 surface area analyzer
(Micromeritics, Norcross, GA). Before each measurement,
MSNs were outgassed in the vacuum (below 0.15 mbar) at
300°C for 16 h, while AEP-MSNs were outgassed at room
temperature. The specific surface areas were calculated
from the adsorption data in the low pressure range using
the Brunauer-Emmett-Teller (BET) model (27). The pore
size distribution was determined following the Barrett-
Joyner-Halenda (BJH) model. Thermogravimetric analysis
(TGA) with a Perkin Elmer TGA7 (Waltham, MA) was
used to measure the amount of amine-containing groups
on the surface of AEP-MSNs. All the samples were tested
under an air atmosphere from 25°C to 800°C at a
heating rate of 10°C/min.
Scheme 1 Preparation and application of pH-sensitive microneedle arrays coated with LB-MSN-OVA. (a) Encapsulation of OVA into AEP-MSNs, followed by
fusion of liposomes (composed of DOPC/DOPS/cholesterol), resulting in LB-MSN-OVA. (b) Adsorption of LB-MSN-OVA onto pH-sensitive microneedles and
penetration of microneedles into human skin, resulting in a pH shift and delivery of LB-MSN-OVA into the viable epidermis and dermis.
MSN delivery
Encapsulation of OVA in AEP-MSNs
For loading of OVA into AEP-MSNs, OVA (0.5 mL, 0.5 mg/
mL‚ 1 mMPB) and AEP-MSN (0.5mL, 2 mg/mL, 1 mMPB)
were mixed and incubated in Eppendorf mixer (400 rpm,
25°C, Nijmegen, the Netherlands) for different time periods
(0, 0.5, 1, 2, 4, 8 and 24 h). After incubation, the suspensions
were centrifuged and the encapsulation efficiency (EE%) of
OVA was determined by measuring the difference in its in-
trinsic fluorescence intensity with a plate reader (Tecan
M1000, Männedorf, Switzerland) (excitation wave-
length = 280 nm and emission wavelength = 320 nm) in the
supernatant before and after the encapsulation.
To determine the maximum loading capacity (LC%) of
OVA in AEP-MSNs, the AEP-MSNs (2 mg/mL) were mixed
with different initial concentrations of OVA (ranging from
0.25, 0.5, 1, 1.5, 2 to 3 mg/mL) and incubated in an
Eppendorf mixer (400 rpm, 25°C) for 0.5 h. Next, the suspen-
sions were centrifuged at 9000 g for 5 min. The EE% of OVA
was determined by measuring the difference in their intrinsic
fluorescence intensity in the supernatant before and after the
encapsulation with a plate reader (Tecan M1000).
The EE% and LC% were calculated as below:
EE% ¼ tova− f ova
tova
 100% ð1Þ
LC% ¼ tova− f ova
OVA loaded AEP−MSNs
 100% ð2Þ
Where tova represents the total content of OVA, and fova is
the content of free OVA (OVA in the supernatant).
Preparation of Liposomes
Liposomes were prepared by dispensing stock solutions of
DOPC, DOPS and cholesterol in a molar ratio of 7/1/2 into
scintillation vials. All lipids were dissolved in chloroform. A
lipid film was generated by slow evaporation of chloroform
in the vial under a nitrogen flow and dried under vacuum
overnight. The lipid film was rehydrated by the addition of
PB (1 mL, 1 mM, pH 7.4) and the mixture was vortexed for
10 s to form a cloudy lipid suspension. The obtained suspen-
sion was sonicated in a water bath for 10 min. The resulting
clear liposomes dispersions were stored at 4°C. To obtain
fluorescent liposomes, a fluorescently labeled lipid (DOPE-
LR) was incorporated into the liposomes by adding the lipids
at 1 wt% DOPE-LR to the lipid solution prior to liposome
formation.
Preparation of LB-MSN-OVA
To prepare LB-MSN-OVA, OVA (0.5 mL, 0.25 mg/mL)
solution in PB (1 mM, pH 7.4) was first transferred into a
2-mL Eppendorf tube, followed by the addition of AEP-
MSNs (0.5 mL, 1 mg/mL) in PB (1 mM, pH 7.4) and lipo-
somes (0.5 mL, 2 mg/mL) in PB (1 mM, pH 7.4). The
resulting mixture was incubated in the Eppendorf mixer for
1.5 h (400 rpm, 25°C). The particles were collected and excess
liposomes and OVA were removed by centrifugation (9000 g,
5 min). The encapsulation efficiency of OVA was determined
by measuring the difference in their intrinsic fluorescence in-
tensity in the supernatant before and after the encapsulation
on a Tecan M1000 plate reader. All experiments were per-
formed in triplicate. For the uptake study of LB-MSN-OVA
in dendritic cells, OVA-AF488 was used to prepare LB-MSN-
OVA.
Characterization of LB-MSN-OVA
The hydrodynamic size distribution was measured with dy-
namic light scattering (DLS) using a Malvern Nano-zs instru-
ment (Worcestershire, UK). Samples were diluted with 1 mM
PB (pH 7.4) and measured 3 times each with 10 runs at 25°C.
The zeta potential was measured by laser Doppler
velocimetry using the same instrument. Samples were diluted
with 1 mM PB (pH 7.4) and measured 3 times with 20 runs.
The size distribution was also measured by NanoSight
LM20 (NanoSight Ltd., Amesbury, UK). Samples were
injected into chamber by an automatic pump (Harvard
Apparatus, catalog no. 98–4362, Holliston MA). The samples
were diluted to 5 μg/ml with 1 mM PB (pH 7.4) and mea-
sured at 25°C. A 90-s video was captured with the shutter set
at 1495 and the gain at 680. The data was analyzed by NTA
2.0 Build 127 software.
Imaging of LB-MSN-OVA was performed by using a
CryoTitan (FEI Corp, Hillsboro, OR) operating at 300 kV
and equipped with a field emission gun (FEG). Cryo-samples
were prepared from a 3 μL droplet of sample solution placed
on the grid inside the Vitrobot™ chamber at 100% relative
humidity and 20°C. Prior to use the TEM grids were glow
discharged by a Cressington 208 carbon coater to render
them hydrophilic. The samples were blotted to remove excess
solution and vitrified by using an automated vitrification robot
(Vitrobot™Mark III, FEI Corp).
OVA Release Studies from AEP-MSNs
and LB-MSN-OVA
To study the influence of ionic strength on the release of OVA
from AEP-MSNs, phosphate buffer (PB, 1 mM Na2HPO4
and 1 mM NaH2PO4 were mixed at molar ratio of 5:2,
pH 7.4) with various concentrations of NaCl (0, 0.9, 1.8, 3.6,
7.2, 14.4 and 28.8%,m/v) were prepared. AEP-MSNs loaded
with OVA (1 mg, based on the mass of AEP-MSNs) were
dispersed in one of the buffers (1 mL) mentioned above. The
suspensions were kept in the Eppendorf mixer for 0.5 h
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(400 rpm, 37°C), followed by centrifugation (9000 g, 5 min) to
collect the supernatant. The amount of released OVA in the
buffer was quantified by measuring the intrinsic fluorescence
intensity of OVA with a Tecan M1000 plate reader. The
released OVA in PB with 0.9, 1.8 and 3.6% NaCl was also
tested by high pressure size-exclusion chromatography (HP-
SEC). Far-UV circular dichroism (CD) spectra ofOVA before
and after release were measured by using a Jasco J-815 spec-
tropolarimeter (Tokyo, Japan). Spectra were collected from
260–190 nm, at 25°C.
To compare the in vitro release of OVA from AEP-MSNs
and LB-MSN-OVA, OVA-loaded AEP-MSNs and LB-
MSN-OVA were dispersed in PBS (pH 7.4) and incubated
in the Eppendorf mixer (400 rpm, 37°C). At various time
points, the suspensions were centrifuged and the supernatants
were replaced with fresh PBS. The amount of OVA released
into the supernatant was determined by measuring the intrin-
sic fluorescence intensity of OVA on a Tecan M1000 plate
reader.
Interaction of LB-MSN-OVA with Bone
Marrow-Derived Dendritic Cells (BMDCs)
Dendritic cells were cultured from BALB/c donor mice as
previously described (28). The study was carried out under
the guidelines compiled by the animal ethic committee of
the Netherlands, and approved by the ethical committee on
animal experiments of Leiden University. Briefly, cell suspen-
sions of bone marrow were obtained by flushing the femurs
and tibia of adult BALB/c mice with culture medium. The
cells (6 × 106 cells/well) were cultured for 10 days in Iscove’s
Modified Dulbecco’s Medium (IMDM) supplemented with
10% (v/v) fetal bovine serum, penicillin and streptomycin
(100 units/ml), 20 μM beta-mercaptoethanol and 20 ng/ml
GM-CSF. The cells were cultured at 37°Cwith 5%CO2. The
medium was refreshed every 2 days.
To study the uptake of nanoparticles, BMDCs (2.5 × 105
cells/ml) were cultured with LB-MSN-OVA containing 6 μg/
ml, 0.6 μg/ml or 0 μg/ml (culture medium) OVA-AF488 for
4 h at either 4°C or 37°C. Free OVA-AF488 solution with the
same concentrations was used as a control. After 4 h, the
uptake of OVA-AF488 was measured using flow cytometry
(FACSCanto II, Becton Dickinson, NJ). To quench the exter-
nal AF488 signal, 0.02% trypan blue was added 5 min before
FACS analysis. The uptake of OVA-AF488 was expressed as
the mean fluorescence intensity (MFI, fluorescence intensity of
each cell in average) in the AF488 channel.
To study the activation of BMDCs by the nanoparticles,
BMDCs (5 × 105 cells/ml) were cultured with LB-MSN-OVA
containing 6 μg/ml, 0.6 μg/ml or 0 μg/ml (culture medium)
OVA-AF488 for 4 h at 37°C. OVA-AF488 solution with the
same concentrations and LPS (1 μg/ml) were used as controls.
The cells were stained for 30 min with a mixture of
300 × diluted anti-CD40-FITC, anti-CD80-PE, and anti-
CD86-APC. The cells were washed and the expression of
CD40, CD80 and CD86 were quantified by flow cytometry.
Modification of Silicon Microneedle Arrays to Obtain
a pH-Sensitive Surface
To coat negatively charged particles onto silicon microneedle
arrays, the microneedles were chemically modified to obtain a
pH-sensitive surface (positively charged at pH 5.8) by using
pyridine groups, as described previously (6). The surface of
silicon was first cleaned by acetone and methanol. Next the
surfaces were hydroxylated by a fresh piranha mixture
consisting of 30% (v/v) H2O2 and 70% (v/v) H2SO4. Then
the surface was incubated with 2% (v/v) APTES in toluene
overnight at room temperature to obtain the amine-modified
silicon surface.
The amine-modified surface was modified with 4-
pyridinecarboxaldehyde (100 mM) in anhydrous isopropanol
with acetic acid (1%, v/v) at room temperature. The obtained
imine bonds on pyridine-modified surface were reduced to a
secondary amine by incubating in NaBH3CN (50 mM) in
isopropanol for 2 h. Finally the modified surface was cleaned
with isopropanol andmethanol and dried in a vacuum oven at
50°C for 0.5 h.
Coating of LB-MSN-OVA on pH-Sensitive Microneedle
Arrays
To determine the level of binding of LB-MSN-OVA on the
microneedle arrays, DOPE-LR was added to the lipids when
the LB-MSN-OVA were prepared. The top of the
microneedle arrays was incubated with LB-MSN-OVA
(50 μl) with a concentration of 0.1, 0.5 and 1 mg/mL in
EDTA buffer (1 mM, pH 5.8) for 2 h at room temperature.
The microneedles were then washed with coating buffer
(450 μl) and the solution was kept for measurement. The
binding efficiency of LB-MSN-OVA was determined by com-
paring the DOPE-LR concentration in the coating solution
before and after coating by using a TecanM1000 plate reader
(Excitation wavelength = 575 nm and Emission wave-
length = 590 nm). The structure, geometry and the surface
morphology of the LB-MSN-OVA coated pH-sensitive
microneedle arrays were examined by scanning electron mi-
croscopy (SEM) in a FEI NOVA nanoSEM 200 (Hillsboro,
OR). The LB-MSN-OVA coated onmicroneedle arrays were
also visualized by Nikon D-Eclipse C1 confocal laser scanning
microscope (CLSM, Tokyo, Japan) with a depth resolution of
5 μm/step, equipped with a 10 × Plan Apo objective. The x
and y resolution was 2.5 μm. An argon laser (488 nm) was
used to visualize OVA-AF488 with a 530/55 emission filter
and a diode-pumped solid-state laser (561 nm) with a 590/55
emission filter was used to visualize DOPE-LR.
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Delivery of LB-MSN-OVA from Microneedles into Ex
Vivo Human Skin
After coated with LB-MSN-OVA, the pH-sensitive
microneedles were pierced into human skin from the abdo-
men, which was used within 24 h after cosmetic surgery from a
local hospital. The study was conducted in accordance to
Helsinki principles and written informed patient consent was
obtained. The microneedles were applied into the skin by an
impact-insertion applicator with a velocity of 54.8 cm/s as
described previously (6). After 1 s, the applicator was removed
and the microneedles were kept inside the skin for 30 min.
Then the microneedles were removed and visualized by scan-
ning electron microscopy (SEM) in a FEI NOVA nanoSEM
200 (Hillsboro, OR). The skin was visualized by Nikon D-
Eclipse C1 CLSM (Tokyo, Japan) with a depth resolution of
5 μm/step, equipped with a 4 × Plan Apo objective. The x
and y resolution was 6.3 μm. An argon laser (488 nm) was
used to visualize OVA-AF488 with a 530/55 emission filter
and a diode-pumped solid-state laser (561 nm) with a 590/55
emission filter was used to visualize DOPE-LR.
Statistical Analysis
All data shown are mean corrected values ± SD of at least
three experiments. The results of cell experiments are ana-
lyzed by Two-way ANOVA with Bonferroni posttests.
RESULTS
Characterization of MSNs and AEP-MSNs
The MSNs were synthesized from the silica precursor
tetraethoxy silane (TEOS) by using a mixture of a nonionic
triblock copolymer (Pluronic P-123) and the cationic fluoro-
carbon surfactant (FC-4) as organic templates. Furthermore
the swelling agent TMB was added to induce the formation of
large-pore MSNs (29). The obtained pristine MSNs were
modified with AEPTMS in order to generate a positively
charged surface (AEP-MSNs). Inspection with TEM revealed
that the negatively charged MSNs were rectangular in shape
with mesochannels along the short axis (Fig. 1a). Modification
with AEPTMS did not alter the morphology or mesostructure
(Fig. 1b), as compared to pristine MSNs. Furthermore, char-
acterization with N2 adsorption-desorption isotherms of both
MSNs and AEP-MSNs showed that these nanoparticles have
typical IV isotherms according to International Union of Pure
and Applied Chemistry (IUPAC) classification (Fig. 1c) (30).
The existence of channel-type mesopores was confirmed by
the existence of a type-H1 hysteresis loop (Fig. 1c) (31). The
values for BET specific surface area (SBET), the total pore
volume (Vt), BJH pore diameter (WBJH) and surface charge
of MSNs and AEP-MSNs are summarized in Table I. It can
be seen that after modification with AEPTMS, SBET, Vt and
WBJH were slightly reduced because of the attachment of the
functionalized silanes on the pore surface. The pore diameter
of the AEP-MSNs was 1–2 nm smaller than that of MSNs
(Fig. 1d), but still sufficiently large to accommodate OVA
(4 × 5 × 7 nm) (22). Dynamic light scattering (DLS) measure-
ments showed that the hydrodynamic diameter of MSNs and
AEP-MSNs was 146.3 ± 0.3 nm and 213.7 ± 0.8 nm, respec-
tively. The observed increase in Z-average size for AEP-
MSNs may be attributed to some particle aggregation, which
is probably due to the decreased charge repulsion among
AEP-MSNs compared to MSNs (Table I).
Encapsulation and Release of OVA from AEP-MSNs
The percentage of grafted amine-containing groups on the
surface of AEP-MSNs was 6.9%, as determined by thermo-
gravimetric analysis (TGA, see Fig. 2a). The encapsulation
efficiency (EE%), defined as the percentage of OVA which is
adsorbed in the MSNs or AEP-MSNs was determined as a
function of incubation time (Fig. 2b). The calibration curve
used to calculate the concentration of OVA is shown in sup-
plementary Fig. 1a. This study revealed that the OVA encap-
sulation within AEP-MSNs was very efficient, as 95 ± 0.4%
(mean ± SD, n = 3) of the protein was encapsulated in the
AEP-MSNs. Furthermore, equilibrium of OVA encapsula-
tion was reached in less than 5 min. In comparison, only
12 ± 2% (mean ± SD, n = 3) of OVA was encapsulated in
negatively charged MSNs after 24 h. The loading capacity
(LC%) of OVA was calculated from the amount of OVA
encapsulated in AEP-MSNs and expressed as the percentage
of the total weight of OVA-loaded AEP-MSNs. The LC% of
OVA in AEP-MSNs was dependent on the initial concentra-
tion of OVA (Fig. 2c). The maximum LC% was 34 ± 4%
(mean ± SD, n = 3) was achieved by increasing the initial
concentration of OVA, indicating a diffusion-driven encapsu-
lation process (32).
To examine the influence of ionic strength of the medium
on the release profile of OVA from the AEP-MSNs, the con-
centration of NaCl in the buffer was varied. The calibration
curve used to calculate the concentration of OVA is shown in
supplementary Fig. 1b. The release percentage of OVA
(defined as the percentage of OVA released from total
encapsulated OVA in AEP-MSNs) increased from
0.6 ± 0.2% (mean ± SD, n = 3) in NaCl-free buffer to
82 ± 2% (mean ± SD, n = 3) in buffer containing 7.2%
NaCl (Fig. 2d). These results demonstrate that the ionic
strength of the medium plays an important role in the release
of OVA, indicating that the interaction between OVA and
AEP-MSNs is mainly electrostatic in nature. The structural
integrity of the released OVA was examined by HP-SEC,
showing that the released OVA was mainly monomeric
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(Fig. 2e), and far-UV CD spectroscopy, indicating that the
secondary structure of released protein was similar to that of
native OVA (supplementary Fig. 2). These results strongly
indicate that encapsulation and release have no adverse effect
on the protein structure.
Preparation and Characterization of LB-MSN-OVA
The OVA-loaded AEP-MSNs had the tendency to pre-
cipitate and form large aggregates (Table I), probably due
to the decreased surface charge upon protein encapsula-
tion (−8.1 ± 1.3 mV, mean ± SD, n = 3). In order to
increase the colloidal stability, the OVA-loaded AEP-
MSNs were stabilized with a lipid bilayer composed of
DOPC, DOPS and cholesterol. For this, liposomes and
OVA-loaded AEP-MSNs were mixed and equilibrated
for 1.5 h and afterwards the excess lipids were removed
by centrifugation. The encapsulation efficiency of OVA in
the resulting lipid-coated AEP-MSNs (LB-MSN-OVA)
was determined to be 74 ± 1%, as compared to
99 ± 1% without lipid (mean ± SD, n = 3). The obtained
LB-MSN-OVA were characterized by DLS, NTA and
TEM. The mean number-based hydrodynamic diameter
(176 ± 11 nm, mean ± SD, n = 3) measured by NTA
(supplementary Fig. 3) was close to the Z-average hydro-
dynamic diameter (190.7 ± 2.7 nm; PDI = 0.125 ± 0.029;
mean ± SD, n = 3) found by DLS (Fig. 3a). The existence
of a lipid bilayer surrounding the AEP-MSNs was con-
firmed by cryoTEM (Fig. 3b and c). The colloidal stability
of the formulation was examined by measuring the hydro-
dynamic diameter and zeta-potential of LB-MSN-OVA
for one week (Fig. 3d-f). It showed that LB-MSN-OVA
slightly changed in diameter and zeta-potential revealing
that the lipid bilayer strongly enhanced the colloidal sta-
bility. The release of OVA from AEP-MSNs and LB-
MSN-OVA was examined in PBS (pH 7.4) for 32 h
Fig. 1 Characterization of the
MSNs and AEP-MSNs. TEM images
of (a) MSNs and (b) AEP-MSNs.
Scale bar = 200 nm. (c) Nitrogen
adsorption-desorption isotherms
and (d) plots of pore diameter vs.
pore volume (inset), calculated from
the desorption isotherms using BJH
model, show that the MSNs and
AEP-MSNs have an average pore
diameter of 10 nm and 9 nm,
respectively.
Table I Physical characteristics of nanoparticles (n = 3)
Sample BETsurface area (m2/g) Pore volume (cm3/g) Pore diameter (nm)a Size (nm) PDI Zeta-potential (mV)b
MSNs 506 1.01 10 ± 1 146.3 ± 0.3 0.154 ± 0.035 −27.8 ± 0.4
AEP-MSNs 318 0.71 9 ± 1 213.7 ± 0.8 0.170 ± 0.062 10.9 ± 0.5
AEP-MSN-OVA - - - 1842 ± 126 0.373 ± 0.056 −8.1 ± 1.3
LB-MSN-OVA - - - 190.7 ± 2.7 0.125 ± 0.029 −24.0 ± 0.7
a Calculated from desorption branch of the N2 sorption isotherms based on the BJH method
b Zeta-potential was measured in 1 mM PB at pH 7.4
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(Fig. 2f). The burst release of OVA from LB-MSN-OVA
was less in comparison to AEP-MSNs, indicating that the
lipid bilayer acts as a barrier retaining the OVA for lon-
ger inside the AEP-MSNs.
Interaction of LB-MSN-OVA with BMDCs
As proteins in serum may interact with the particles, the col-
loidal stability of LB-MSN-OVA in cell culture medium was
Fig. 2 (a) Thermogravimetric analysis (TGA) curves of MSNs and AEP-MSNs. (b) Encapsulation kinetics of OVA into MSNs and AEP-MSNs (mean ± SD,
n = 3), concentration of OVA is 0.5 mg/mL and MSNs (AEP-MSNs) is 2 mg/mL. (c) Loading capacity (LC%) of OVA into AEP-MSNs (mean ± SD, n = 3) at
different initial concentration of OVA. (d) Influence of ionic strength on OVA release from AEP-MSNs (mean ± SD, n = 3). (e) HP-SEC chromatograms of the
released OVA from AEP-MSNs. (f) Release profiles of OVA from AEP-MSNs and LB-MSN-OVA in PBS (pH 7.4) (mean ± SD, n = 3).
Fig. 3 Characterization of LB-MSN-OVA. (a) Hydrodynamic diameter of LB-MSN-OVA determined by DLS. (b) CryoTEM image of AEP-MSNs, and (c) LB-
MSN-OVA, revealing a lipid bilayer thickness of ~4 nm (indicated by white arrows), scale bar= 100 nm. (d-f) colloidal stability of OVA-loaded AEP-MSNs and LB-
MSN-OVA over one week: (d) hydrodynamic diameter, (e) polydispersity index and (f) zeta potential).
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studied. Only limited aggregation of the nanoparticles was
observed and a modest amount of OVA (15%) was released
after 4 h (supplementary Table 1). To examine whether LB-
MSN-OVA facilitate the uptake by BMDCs, the uptake of
LB-MSN-OVA was assessed by flow cytometry and com-
pared to that of free OVA solution. As shown in Fig. 4, at
4°C there was almost no uptake (no significance compared to
culture medium only) of LB-MSN-OVA or OVA in BMDCs
(Fig. 4a), indicating that the uptake of LB-MSN-OVA and
OVA is mediated by an active process. At 37°C the fluores-
cent level of LB-MSN-OVA treated cells was significantly
higher (P<0.001) than that for free OVA-AF488 with the
OVA concentration of 6 μg/ml (Fig. 4b). There was no sig-
nificant difference found between LB-MSN-OVA and free
OVA at lower concentration. These results indicate that LB-
MSN-OVA are capable of promoting antigen uptake by
antigen-presenting cells (BMDCs). In order to study the acti-
vation of BMDCs by the nanoparticles, BMDCs were incu-
bated with different formulations for 4 h and the expression of
CD40, CD80 and CD86 was measured. Whereas exposure to
LPS led to a significant upregulation of these activation
markers, LB-MSN-OVA did not induce increased expression
of CD40, CD80 or CD86 on dendritic cells compared to free
OVA or cell culture medium (Fig. 4c).
Coating of LB-MSN-OVA on Microneedles
Next, we investigated whether the LB-MSN-OVA could be
adsorbed onto a siliconmicroneedle array via physical adsorp-
tion. First, the pH-sensitive pyridine-modified microneedle
arrays were prepared as described previously (6). The
microneedle arrays were coated with LB-MSN-OVA at
pH 5.8 in an EDTA buffer (1 mM). To determine the optimal
concentration of LB-MSN-OVA for the coating process, the
nanoparticle concentration was varied in the buffered coating
solution. Increasing the LB-MSN-OVA concentration result-
ed in increased amounts of LB-MSN-OVA coated onto the
microneedle array surfaces. However, the coating efficiency is
reduced (Table II). The lowest coating efficiency obtained was
16 ± 2.7% (mean ± SD, n = 3), corresponding to 7.9 ± 1.3 μg
(mean ± SD, n = 3) and 1.5 ± 0.24 μg (mean ± SD, n = 3) of
LB-MSN-OVA and OVA, respectively coated on the
microneedle array. Considering the surface area of the
microneedles accounts for 40% of the total surface area of
microneedle arrays, 3.2 ± 0.5 μg (mean ± SD, n = 3) of
nanoparticles and 0.58 ± 0.10 μg (mean ± SD, n = 3) of
OVA were coated onto the microneedle surface of one array.
Scanning electron microscopy imaging was used to visual-
ize the presence of the LB-MSN-OVA on the pyridine-
modifiedmicroneedle arrays (Fig. 5a-f). Compared to untreat-
ed pyridine-modified arrays (Fig. 5a-c), a high number of
nanoparticles were observed on the surface of the
microneedles (Fig. 5d-f) after coating with LB-MSN-OVA.
To determine whether the OVA and nanoparticles
colocalized on the microneedles, the LB-MSN-OVA coated
microneedles were visualized by CLSM. For this experiment,
we used OVA-AF488 and DOPE-LR enabling the visualiza-
tion of both the protein and lipids. Imaging revealed that the
fluorescent labels were both located at the microneedle sur-
faces indicative of the integrity of the LB-MSN-OVA upon
physical adsorption (Fig. 6a-c). This showed us that LB-MSN-
OVA could be immobilized onto microneedles via electrostat-
ic interaction.
Delivery of LB-MSN-OVA into Human Skin
Next, the delivery of LB-MSN-OVA from the surface of
microneedles into the skin was studied. For this, the
nanoparticle-coated microneedle arrays were applied onto
human skin ex vivo for 30 min and subsequently withdrawn.
Next the intradermal delivery was studied by both SEM and
CLSM. Less particles were observed on surface of
microneedles after the penetration and withdrawal from hu-
man skin (Fig. 5g-i). Colocalization of the fluorescence from
both OVA-AF488 and DOPE-LR was observed inside the
skin (Fig. 6d-f), illustrating that the microneedles penetrated
into the skin and successfully delivered the LB-MSN-OVA.
DISCUSSION
An alarming trend towards decreased vaccine compliance in
the western world emphasizes the need to develop effective,
but also safe and easily administrable vaccines. In this respect
dermal vaccination is interesting as the skin provides an easily
accessible (and potentially painless) route of administration
and also provides an environment which is very conductive
for the initiation of immunological memory. Topical admin-
istration of vaccines is often not effective as bulky vaccines do
not permeate the skin. Recently, we and other groups have
shown that antigens can effectively be delivered into the epi-
dermis and dermis by means of coated microneedles
(3,4,10,33). However, some major challenges remain, which
include the effective dose that can be delivered with coated
microneedles and the immunogenicity of the subunit vaccines
(4,6).
Here we introduce a novel carrier system for subunit vac-
cines with a high loading efficiency that effectively delivers a
model antigen into the skin using a complementary charged
microneedle array. To our best knowledge, the current study
is the first example of a microneedle-mediated intradermal
delivery system for mesoporous nanoparticles, which could
be a promising tool to deliver a wide range of compounds into
the skin. High loading efficiency was achieved by encapsulat-
ing the model antigenOVA into surface-modified MSNs with
large pores (>10 nm). We chose MSNs because of their
MSN delivery
advantageous properties, including large surface area, con-
trolled particle size and pore structure as well as ease of surface
modification. Moreover, a previous study showed that subcu-
taneous immunization with 2 μg of OVA-loaded MSNs in-
duced comparable antibody responses as 50 μg OVA
adjuvanted with Quil-A (18), demonstrating that antigen-
loaded MSNs can elicit an immune response at reduced anti-
gen doses compared to a conventional delivery system. Our
results indicate that one of the reasons for the immune en-
hancing effect on MSNs may be the increased uptake by den-
dritic cells when OVA is associated with MSNs (Fig. 4). LB-
MSN-OVA do not increase the activation of dendritic cells
compared to free OVA, which is in line with previous findings
(34). Similar results were also reported with OVA-loaded
PLGA nanoparticles (35) as OVA-loaded PLGA nanoparti-
cles were found not to increase activation of human
monocyte-derived dendritic cells (MHC II, CD83 and
CD86). This suggests that the addition of adjuvants capable
of inducing DC maturation, may further increase the immu-
nogenicity of LB-MSN-OVA.
For an efficient dermal delivery of nanoparticulate vac-
cines, MSNs are required that are small in size. In addition,
they should have large pores (inner diameter > 5 nm) in order
to encapsulate large amounts of proteins. Most nanosized
MSNs do not fit these criteria, although recently some exam-
ples have emerged, mainly for the delivery of DNA/RNA
(24,36–39). MSNs with a large pore size of about 10 nm,
recently developed in our lab (26), were used in the current
study to accommodate the relatively large OVA molecules
(4 × 5 × 7 nm). The encapsulation study showed that the
synthesized MSNs can accommodate a large amount of
OVA within 5 min after mixing AEP-MSNs with OVA. It
has been reported that MSNs with a pore size of 3.6 and
2.3 nm had a maximum OVA LC% of 21.8% (1) and 7.2%
(18), respectively. The even higher maximum LC% of OVA
in our study of 33.9% may be due to the larger pore size.
Fig. 4 The uptake of LB-MSN-
OVA in BMDCs at 4°C (a) and
37°C (b), and the activation of
BMDCs by LB-MSN-OVA (c). Bars
represent mean ± SD, n = 3. The
uptake of OVA-AF488 and
expression of CD40, CD80 and
CD86 were expressed as the mean
fluorescence intensity (MFI). ***
P<0.001.
Table II Coating amount of LB-
MSN-OVA and OVA on
microneedle arrays
Amount of LB-MSN-OVAa (μg) Coated LB-MSN-OVA (μg) Coated OVAb (μg) Coating efficiency (%)
5 1.3 ± 0.2 0.24 ± 0.03 27 ± 3
25 5.4 ± 1.7 1.0 ± 0.3 22 ± 7
50 7.9 ± 1.3 1.5 ± 0.2 16 ± 3
a The amount of LB-MSN-OVA in coating solution; b The amount of coated OVA was calculated from the loading
capacity of OVA and the coating amount of LB-MSN-OVA. All the coating amounts are expressed as the amount of AEP-
MSNs and are based on one microneedle array which contains 576 needles per array. All the results are based on 3
independent microneedle arrays
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To coat nanoparticles onto the pyridine-modified
microneedles, the nanoparticles should have a negative sur-
face charge allowing for adsorption based on electrostatic in-
teractions, and a good colloidal stability allowing uniform and
reproducible coating. In our study, negative liposomes were
used to fuse to the surface of the positively charged AEP-
MSNs, to achieve a negative surface charge. This fusionmeth-
od was previously used for coating fluorophore (40), photo-
sensitizers (41) and DNA loaded MSNs (23) and was reported
to be based on the electrostatic interaction between the lipids
and surface of MSNs (23). The fusion of lipid bilayer onMSN
surface has been shown to be able to modify the charge, im-
prove the stability of MSNs and contain the drug inside the
pores ofMSNs. In order to prepare the liposomes, DOPC and
cholesterol were used because in a previous study liposomes
containing DOPC and cholesterol were shown to be able to
stabilize drug-, small interfering RNA- and toxin-loaded
MSNs (25). DOPS was used to give the liposomes a negative
charge, which is needed to coat the nanoparticles onto the
positively charged microneedles. Our results show that the
colloidal stability of OVA-loaded MSNs was improved after
liposome fusion and the lipid bilayer generated a negatively
charged surface on LB-MSN-OVA. The LB-MSN-OVA
were coated onto microneedles at pH 5.8 where more than
90% of the pyridine groups are positively charged (6).
Combined with the low ionic strength of the buffer, this allows
for the binding of the negatively charged LB-MSN-OVA via
electrostatic interactions. The presence of the lipid bilayer on
the surface of MSNs was confirmed by cryoTEM and indicat-
ed by the change of surface charge (from +11 mV to
−24.0 mV at pH 7.4). The encapsulation efficiency of OVA
was decreased by about 25% after the fusion of liposomes,
which may be because the negatively charged lipid bilayer
and OVA were competing with each other for the binding
on the MSN surface and some of the OVA coated on the
AEP-MSN surface may be replaced by the lipid bilayer. The
Fig. 5 SEM images of pyridine-modified microneedle arrays before the adsorption of LB-MSN-OVA with different magnifications (a: 80 ×; b: 2000 ×; c: 5000
×), after the adsorption of LB-MSN-OVAwith different magnifications (d: 80×; e: 2000×; f: 5000×) and after the penetration of human skin (g: 80×; h: 2000
×; i: 5000 ×).
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release study showed that the coated lipid bilayer functioned
as a gate and prolonged the release of the antigen, which could
be important for the nanoparticles to remain their adjuvant
effect (35).
The binding of LB-MSN-OVA on microneedles was visu-
alized by both SEM and CLSM. The SEM images showed
that after coating the microneedles with LB-MSN-OVA, the
surface of the microneedles became rougher, but the sharp-
ness of the microneedles was not affected. One major disad-
vantage of coated microneedles is the limited amount of ma-
terials that can be coated onmicroneedles because of the small
surface area. The amount of LB-MSN-OVA coated on one
microneedle array was 7.9 μg and was higher than that of
inactivated polio virus (IPV) in a previous study (100 ng)
(33). Thus next to improving the immunogenicity of antigens,
LB-MSN-OVA could also provide an effective way of increas-
ing the antigen dose coated on microneedles. This may be
because LB-MSN-OVA have a lower zeta potential than
IPV under similar conditions (−16.8 mV vs − 7.8 mV in
1mMEDTA at pH 5.8). In our study the coatedOVA loaded
in LB-MSN-OVA is 1.5 μg on one microneedle array and is
much higher than the amount of coated IPV (33) in a previous
study. Other possibilities to increase the delivered amount of
antigen are increasing the number of microneedle arrays used
or increasing the number of needles on one array.
To effectively deliver antigens into the skin, next to efficient
coating of the antigen on the microneedles, rapid dissolution
from the microneedles once inserted into the skin, is critical.
The pH-sensitive microneedles used in the present study were
developed in our lab for the intradermal delivery of vaccines
by coating antigens at slightly acidic pH and releasing them at
physiological pH. CLSM images showed that the LB-MSN-
OVA were successfully released into the holes made by the
microneedles. The fluorescence from lipids and OVA was
found to still co-localize with each other in the holes made
by microneedles, indicating that the LB-MSN-OVA may be
still intact after the release. This would be important for LB-
MSN-OVA to remain their adjuvant effect (25).
Thus, the developed system combines the advantages of
microneedles and nanoparticles. Microneedles allow non-
invasive delivery of vaccines into skin and antigen-loaded
nanoparticles have the potential to increase and modify the
immune response against the antigen. In addition, by coating
the nanoparticles onto the pH-sensitive pyridine-modified
microneedles, the separate application of antigen after
microneedle penetration is avoided. An important concern is
the bio-distribution of MSNs after intradermal delivery.
Studies have shown that intravenously injected MSNs were
mainly excreted out of mice through urine and feces,
indicating thatMSNs are biodegradable (42) and other studies
showed that MSNs can undergo hydrolysis to form non-toxic
silica acid (43). However, as deposition in the skin may alter
the biodistribution and clearance of the MSNs, systematic
studies need to be performed in order to assess the safety of
these nanoparticles in animals and humans.
CONCLUSION
In conclusion, the LB-MSN-OVA coated microneedle arrays
represent a novel intradermal antigen delivery system. The
large pores of MSNs enabled the rapid encapsulation of
Fig. 6 CLSM images of LB-MSN-
OVA coated microneedles (a-c).
Red: DOPE-LR (a); Green: OVA-
AF488 (b); Merged (c). The x and y
arrows show that the scanning area
is 1200 μm× 1200 μm large. The
z arrow indicates the scanning
depth of 200 μm. CLSM images of
human skin after removal of the LB-
MSN-OVA coated microneedle
arrays (d-f). Red: DOPE-LR (d);
Green: OVA-AF488 (e); Merged
(f). The x and y arrows show that
the scanning area is
3180 μm × 3180 μm large. The z
arrow indicates the scanning depth
of 280 μm.
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OVA with a high loading capacity. The introduction of lipid
bilayers significantly improved the colloidal stability of OVA-
loaded AEP-MSNs and concomitantly reduced the prema-
ture release of OVA. In addition, it enabled the coating of
the nanoparticles on the surface of pH-sensitive microneedle
arrays. Application of LB-MSN-OVA coated microneedle ar-
rays into human skin (ex vivo) resulted in the successful delivery
of the OVA-loaded nanoparticles into the skin. The method is
not restricted to the delivery of antigens, but may also be
useful to deliver any compound that can be encapsulated in
MSNs like (low-molecular-weight) drugs, RNA, DNA and
proteins.
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